NCT05858450View on ClinicalTrials.gov

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

CompletedOBSERVATIONAL

Enrollment

3,442,996

Participants

Timeline

Start Date

May 5, 2023

Primary Completion Date

May 12, 2023

Study Completion Date

May 12, 2023

Conditions

Influenza, HumanCOVID-19

Interventions

BIOLOGICAL

Comirnaty

COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.

BIOLOGICAL

Quadrivalent Influenza Vaccine

Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines

Trial Locations (1)

10001

Pfizer, New York